Necitumumab Fails to Improve Survival in Lung Cancer (NSCLC)
Addition of necitumumab to cisplatin and pemetrexed did not increase survival in stage IV non-squamous non-small cell lung cancer (NSCLC).
Diagnosis & Disease Information
Weekly Docetaxel Plus Cisplatin Not Superior to Docetaxel Monotherapy in Elderly Lung Cancer
Weekly docetaxel plus cisplatin is not superior to docetaxel monotherapy for elderly advanced non-small cell lung cancer (NSCLC).
No Survival Benefit with Post-Chemo Stereotactic Radiosurgery in Non-Small Cell Lung Cancer
Non-small cell lung cancer and oligo-brain metastases receiving stereotactic radiosurgery followed by chemotherapy did not see an improvement in survival.
In ALK-Rearranged Lung Cancer with Brain Metastases, Crizotinib Provides Disease Control
Crizotinib associated with systemic and intracranial disease control in patients with ALK-rearranged non-small cell lung cancer (NSCLC).
Standard-Dose vs. High-Dose Chemoradiotherapy With, Without Cetuximab for Lung Cancer
High-dose radiotherapy was not better than standard-dose for non-small cell lung cancer (NSCLC).
The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer
[Clinical Medicine Insights: Oncology] Performance status is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), but pharmacogenomic markers may also correlate with outcome. This study attempts to correlate clinical and pharmacogenomic measures with overall survival.
For Non-Small Cell Lung Cancer, Nivolumab Superior to Docetaxel
CheckMate-017 study evaluating Opdivo (nivolumab) versus docetaxel in non-small cell lung cancer (NSCLC) was stopped early.
For Elderly Patients with Lung Cancer, Biweekly Paclitaxel Plus Carboplatin Found Safe, Effective
Biweekly paclitaxel and carboplatin is effective and well-tolerated in elderly patients with advanced non-small cell lung cancer (NSCLC).
Vorinostat May Improve Efficacy of Gefitinib in EGFR-Mutant Non-Small Cell Lung Cancer
Combination of gefitinib and vorinostat is well tolerated in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC).
For Non-Small Cell Lung Cancer, Bevacizumab Plus Chemotherapy Not Effective
Bevacizumab, paclitaxel, and carboplatin did not achieve the prespecified objective response rate goal for non-small cell lung cancer.
- Loading...
Loading...
Loading... 
Loading...